Friday, 02 December 2022

ZeNix trial shows effectiveness of BPaL regimen for drug-resistant TB

01 September 2022 | News

The effectiveness can be maintained with reduced dosing of Linezolid

Image credit: yandex.com

Image credit: yandex.com

The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with reduced dosage and/or duration of the linezolid component of the regimen. Along with the maintenance of efficacy, there was a decrease in linezolid-associated side effects that accompanied the reduced dosage or duration of linezolid. The results from the trial, which was led by TB Alliance, a global non-profit TB drug developer, were published in the New England Journal of Medicine. 

 

A government-led study of the regimen in India called mBPaL commenced in October 2021 and is now enrolling patients at three sites out of a planned 11. It is scheduled to reach its primary completion in 2023 after enrolling 400 patients. 

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account